Blueprint Medicines Corporation

NasdaqGS:BPMC Lagerbericht

Marktkapitalisierung: US$6.6b

Blueprint Medicines Management

Management Kriterienprüfungen 3/4

Blueprint Medicines' CEO ist Kate Haviland, ernannt in Apr 2022, hat eine Amtszeit von 2.08 Jahren. Die jährliche Gesamtvergütung beträgt $6.43M, bestehend aus 12.2% Gehalt und 87.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.096% der Aktien des Unternehmens, im Wert von $6.16M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.7 Jahre bzw. 9 Jahre.

Wichtige Informationen

Kate Haviland

Geschäftsführender

US$6.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts12.2%
Amtszeit als Geschäftsführer2.2yrs
Eigentum des Geschäftsführers0.1%
Durchschnittliche Amtszeit des Managements3.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder9.1yrs

Jüngste Management Updates

Recent updates

Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 05
Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Blueprint Medicines: Rampant Growth Mostly Priced In

May 04

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Apr 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)

Apr 05
Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)

Feb 20

Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Jan 08
Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Dec 18
Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Nov 20
Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Jul 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Apr 16
Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 09
Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Dec 12
Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Nov 07
Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal

Sep 15

Blueprint to seek label expansion for systemic mastocytosis therapy after trial win

Aug 17

Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance

Aug 02

Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront

Jun 30

Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook

Feb 17
Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Kate Haviland im Vergleich zu den Einnahmen von Blueprint Medicines verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

-US$288m

Dec 31 2023US$6mUS$782k

-US$507m

Sep 30 2023n/an/a

-US$555m

Jun 30 2023n/an/a

-US$554m

Mar 31 2023n/an/a

-US$581m

Dec 31 2022US$6mUS$701k

-US$558m

Sep 30 2022n/an/a

-US$718m

Jun 30 2022n/an/a

-US$702m

Mar 31 2022n/an/a

-US$650m

Dec 31 2021US$4mUS$501k

-US$644m

Sep 30 2021n/an/a

-US$411m

Jun 30 2021n/an/a

US$340m

Mar 31 2021n/an/a

US$325m

Dec 31 2020US$2mUS$461k

US$314m

Sep 30 2020n/an/a

US$333m

Jun 30 2020n/an/a

-US$395m

Mar 31 2020n/an/a

-US$371m

Dec 31 2019US$3mUS$432k

-US$348m

Sep 30 2019n/an/a

-US$362m

Jun 30 2019n/an/a

-US$340m

Mar 31 2019n/an/a

-US$267m

Dec 31 2018US$3mUS$393k

-US$237m

Sep 30 2018n/an/a

-US$205m

Jun 30 2018n/an/a

-US$170m

Mar 31 2018n/an/a

-US$177m

Dec 31 2017US$1mUS$353k

-US$148m

Vergütung im Vergleich zum Markt: KateDie Gesamtvergütung ($USD6.43M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD8.49M).

Entschädigung vs. Einkommen: KateDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Kate Haviland (48 yo)

2.2yrs

Amtszeit

US$6,432,012

Vergütung

Ms. Kathryn Haviland, also known as Kate, is Director of Bicara Therapeutic, Inc. from October 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serves as President, Chie...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Kathryn Haviland
President2.2yrsUS$6.43m0.096%
$ 6.3m
Alexis Borisy
Co-Founder & Directorno dataUS$397.33k0.11%
$ 7.3m
Michael Landsittel
Chief Financial Officer8.3yrsUS$2.19m0.064%
$ 4.2m
Christina Rossi
Chief Operating Officer2.2yrsUS$2.81m0.044%
$ 2.9m
Percy Carter
Chief Scientific Officer3.1yrsUS$2.30m0.067%
$ 4.4m
Fouad Namouni
President of Research & Development3.8yrsUS$2.80m0.044%
$ 2.9m
Ariel Hurley
Senior VP1.4yrskeine Daten0.024%
$ 1.6m
Christopher Murray
Chief Technical Operations & Quality Officer6.7yrsUS$3.79m0.054%
$ 3.6m
Jenna Cohen
Senior Director & Head of Investor Relationsno datakeine Datenkeine Daten
Tracey McCain
Executive VP7.8yrsUS$2.34m0.046%
$ 3.1m
Debra Durso-Bumpus
Chief People Officer4.3yrskeine Daten0.042%
$ 2.8m
Julian Baker
Senior Vice President of Corporate Affairsno datakeine Datenkeine Daten

3.8yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: BPMCDas Führungsteam des Unternehmens gilt als erfahren (3.7 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Kathryn Haviland
President2.2yrsUS$6.43m0.096%
$ 6.3m
Alexis Borisy
Co-Founder & Director13.2yrsUS$397.33k0.11%
$ 7.3m
George Demetri
Chair of Scientific Advisory Board12.1yrsUS$333.38kkeine Daten
Lynn Seely
Lead Independent Director8.2yrsUS$452.33k0.013%
$ 887.6k
Charles Sawyers
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Brian Druker
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Nicholas Lydon
Member of Scientific Advisory Board & Independent Director13.2yrsUS$417.33k0.085%
$ 5.6m
Lonnel Coats
Independent Director8.3yrsUS$419.33k0.013%
$ 887.6k
William Hahn
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Scott Lowe
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Daniella Beckman
Independent Director2.5yrsUS$422.33k0.0078%
$ 513.5k
Jeffrey Albers
Chairman9.9yrsUS$526.08k0.24%
$ 15.7m

9.1yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: BPMCDie Vorstandsmitglieder gelten als erfahren (9 Jahre durchschnittliche Amtszeit).